12 research outputs found
Characterization of exosomes in peritoneal fluid of endometriosis patients
Objective: To demonstrate the feasibility of studying exosomes directly from peritoneal fluid, we isolated exosomes from endometriosis patient samples and from controls, and characterized their cargo.
Design: Case-control experimental study.
Setting: Academic clinical center.
Patient (s): Women with and without endometriosis who underwent laparoscopic surgery (n ¼ 28 in total).
Intervention (s): None.
Main Outcome Measure (s): Concentration of exosomes within peritoneal fluid and protein content of the isolated exosomes.
Result (s): Peritoneal fluid samples were pooled according to the cycle phase and disease stage to form six experimental groups, from
which the exosomes were isolated. Exosomes were successfully isolated from peritoneal fluid in all the study groups. The concentration
varied with cycle phase and disease stage. Proteomic analysis showed specific proteins in the exosomes derived from endometriosis
patients that were absent in the controls. Five proteins were found exclusively in the endometriosis groups: PRDX1, H2A type 2-C,
ANXA2, ITIH4, and the tubulin a-chain.
Conclusion (s): Exosomes are present in peritoneal fluid. The characterization of endometriosis-specific exosomes opens up new
avenues for the diagnosis and investigation of endometriosi
Protocol for a longitudinal, prospective cohort study investigating the biology of uterine fibroids and endometriosis, and patients' quality of life: the FENOX study
INTRODUCTION:Millions of women suffer from the consequences of endometriosis and uterine fibroids, with fibroids the cause for over 50% of hysterectomies in the USA, and direct costs for their treatment estimated at between US9 billion. Endometriosis commonly affects millions of women worldwide predominantly during reproductive age, with severe menstrual and non-menstrual pain and subfertility the main symptoms. Due to the 'unhappy triad' of endometriosis-lack of awareness, lack of clinically relevant biomarkers and the unspecific nature of symptoms-women wait on average for 8-12 years before the definitive endometriosis diagnosis is made. Treatment options for both conditions are not satisfactory at the moment, especially with a view to preserving fertility for the women and families affected. In the Fibroids and Endometriosis Oxford (FENOX) study, we combine the investigation of fibroids and endometriosis, and plan to collect high-quality tissue samples and medical data of participants over a time frame of 5 years after surgical intervention.
METHODS AND ANALYSIS:Biological samples such as blood, saliva, urine, fat, peritoneal fluid and-if found-endometrial tissue or fibroids as well as detailed clinical and intraoperative data will be collected from women undergoing surgery and participating in the study after informed consent. We plan to recruit up to 1200 participants per disease arm (ie, endometriosis and uterine fibroids) over 5 years. Participants will fill in detailed and validated questionnaires on their medical history and quality of life, with follow-ups for 5 years. Enrolment started on 2 April 2018, and FENOX will close on 31 March 2028. We will analyse the biological samples using state-of-the-art molecular biology methods and correlate the findings with the medical records and questionnaire data.
ETHICS AND DISSEMINATION:The findings will be published in high-ranking journals in the field and presented at national and international conferences.
TRIAL REGISTRATION NUMBER:ISRCTN13560263
Using analytic hierarchy process with GIS for Dengue risk mapping in Kolkata Municipal Corporation, West Bengal, India
Mapping of mosquito-borne diseases in Kolkata Municipal Corporation using GIS and AHP based decision making approach
Prevalence and Determinants of Overweight, Obesity, and Type 2 Diabetes Mellitus in Adults in Malaysia
Diagnostic accuracy of reused Pronto Dry® test and CLOtest® in the detection of Helicobacter pylori infection
Exosomes and breast cancer drug resistance
Lymphatic filariasis (LF) is a vector-borne parasitic disease that is being targeted for elimination through mass drug administration (MDA). The co-distribution of Loa loa in Central Africa poses a significant barrier to the expansion of the MDA due to risk of severe adverse events (SAEs) associated with the drug ivermectin that is routinely used. National LF programmes are yet to significantly scale up in co-endemic areas and need a practical approach to make preliminary decisions based on the mapping status and potential treatment strategies. We reviewed relevant data available to WHO and in the literature for LF-L. loa endemic countries to develop a simple method to support the scale-up of MDA to eliminate LF. A basic model for national LF programmes to work from at the administrative or implementation unit (IU) level has been developed for LF - L. loa co-endemic countries. The model includes five practical steps, which comprise the development of a national filarial database and a simple classification system to help determine the mapping status and most appropriate treatment strategy. Steps are colour-coded and linked to a general decision tree, which is also presented. This IU-level model is simple to follow and will help LF elimination programmes develop an action plan and scale up the implementation of alternative treatment strategies in L. loa co-endemic areas. The model could be further developed to incorporate the additional complexity of IUs where an intervention is required to eliminate onchocerciasis, particularly in hypo-endemic areas where ivermectin has not been used